These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 15329922

  • 21. The Hyper-CVAD Regimen is an Optimal Pediatric-inspired Regimen for Adolescents and Adults With Acute Lymphoblastic Leukemia.
    Jabbour E, Kantarjian H.
    Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):63-65. PubMed ID: 33191168
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Permanent insulin-dependent diabetes mellitus in a patient with acute lymphoblastic leukemia.
    Akane Y, Yamamoto M, Igarashi K, Takebayashi A, Hori T.
    Pediatr Int; 2020 Mar; 62(3):403-405. PubMed ID: 32022381
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine.
    Garcia M, Romaguera JE, Inamdar KV, Rassidakis GZ, Medeiros LJ.
    Cancer; 2009 Mar 01; 115(5):1041-8. PubMed ID: 19170236
    [Abstract] [Full Text] [Related]

  • 34. Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy.
    Dixit A, Chatterjee T, Mishra P, Kannan M, Choudhry DR, Mahapatra M, Choudhry VP, Saxena R.
    Clin Appl Thromb Hemost; 2007 Jul 01; 13(3):292-8. PubMed ID: 17636191
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Feasibility and outcome of the hyper-CVAD regimen in patients with adult acute lymphoblastic leukemia.
    Portugal RD, Loureiro MM, Garnica M, Pulcheri W, Nucci M.
    Clin Lymphoma Myeloma Leuk; 2015 Jan 01; 15(1):52-7. PubMed ID: 25037887
    [Abstract] [Full Text] [Related]

  • 39. [Transient dysfibrinogenemia and cerebral thrombosis following remission induction therapy for acute lymphoblastic leukemia].
    Kubota T, Okamura T, Hayashi S, Nagafuchi S, Ohtsuka T, Shibuya T, Harada M, Niho Y.
    Rinsho Ketsueki; 1990 Sep 01; 31(9):1517-22. PubMed ID: 2246826
    [Abstract] [Full Text] [Related]

  • 40. Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines.
    Ronghe M, Burke GA, Lowis SP, Estlin EJ.
    Cancer Treat Rev; 2001 Dec 01; 27(6):327-37. PubMed ID: 11908926
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.